肝切除与术中微波消融治疗≤5cm单发肝细胞癌的倾向评分匹配分析
本研究回顾性比较肝切除与术中微波消融治疗单发≤5cm肝细胞癌的疗效,经倾向评分匹配后各94对患者,两组5年和10年总生存率及无复发生存率均无统计学差异;亚组分析显示肿瘤>3cm时肝切除无复发生存更优。
要点
- ≤5cm单发肝细胞癌,肝切除与微波消融的总生存和无复发生存无显著差异
- 肿瘤>3cm且肝功能良好者,肝切除无复发生存优于微波消融
- 倾向评分匹配后两组基线变量包括肝功能和肿瘤大小均衡
核心结论
- 倾向评分匹配研究证实,对于单发≤5cm肝细胞癌,肝切除与微波凝固坏死治疗在总生存率和无复发生存率上均无统计学显著差异。
- 然而,当肿瘤大小>3cm且患者肝功能良好时,推荐行肝切除。
研究设计与样本
- 回顾性队列研究,1994年至2015年单中心551例单发≤5cm肝细胞癌患者,肝切除128例,微波凝固坏死治疗423例。
- 采用倾向评分匹配分析识别94对匹配患者比较结局。
主要发现
- 匹配后两组基线变量包括肝功能和肿瘤大小均衡。
- 肝切除组5年和10年总生存率分别为76%和47%,微波凝固坏死治疗组分别为77%和48%(P = .865)。
- 肝切除组5年和10年无复发生存率分别为55%和41%,微波凝固坏死治疗组分别为47%和32%(P = .377)。
- 亚组分析中,肿瘤大小>3cm患者肝切除组5年无复发生存率为56.5%,微波凝固坏死治疗组为32.4%(P = .029)。
临床怎么用
- 对于单发≤5cm肝细胞癌,肝切除与微波消融均可作为治疗选择,总生存和无复发生存相似。
- 肿瘤>3cm且肝功能良好时,优先考虑肝切除以改善无复发生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little evidence exists regarding the perioperative and oncologic benefits of microwave ablation for hepatocellular carcinoma. The aim of this study was to compare the efficacy of hepatic resection and operative microwave ablation (microwave coagulo-necrotic therapy) for single hepatocellular carcinoma ≤5 cm. METHODS: Between 1994 and 2015, a total of 551 patients with a single hepatocellular carcinoma ≤5 cm were treated in our institution (hepatic resection: n = 128; microwave coagulo-necrotic therapy: n = 423). We compared overall survival and recurrence-free survival between hepatic resection and microwave coagulo-necrotic therapy. Propensity score matching analysis identified 94 matched pairs of patients to compare outcomes. RESULTS: After propensity score matching, baseline variables, including liver function and tumor size, were well-balanced between the 2 groups. The 5- and 10-year overall survival rates were 76% and 47% for hepatic resection and 77% and 48% for microwave coagulo-necrotic therapy, respectively (P = .865). The 5- and 10-year recurrence-free survival rates were 55% and 41% for hepatic resection and 47% and 32% for microwave coagulo-necrotic therapy, respectively (P = .377). In the subgroup analysis, the hepatic resection group had better recurrence-free survival than the microwave coagulo-necrotic therapy group in patients with tumor size >3 cm, with 5-year recurrence-free survival rates of 56.5% and 32.4% in the hepatic resection and microwave coagulo-necrotic therapy group, respectively (P = .029). CONCLUSION: Our propensity score matching study confirmed no statistically significant differences in both overall survival and recurrence-free survival between hepatic resection and microwave coagulo-necrotic therapy for single hepatocellular carcinoma ≤5 cm; however, hepatic resection is recommended for hepatocellular carcinoma with tumor size >3 cm when patients have good liver function.
引用
- Ryu T, Takami Y, Wada Y, et al. Hepatic resection versus operative microwave ablation for single hepatocellular carcinoma ≤5 cm: A propensity score-matched analysis. Surgery. 2019. PMID: 31279438. doi:10.1016/j.surg.2019.05.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。